Abstract #812: Prevalence of Established Diabetes Mellitus in Patients with Primary Hyperparathyroidism

2005 ◽  
Vol 11 ◽  
pp. 43
Author(s):  
Monica Giselle Cardenas ◽  
Karen J. Vigil ◽  
D. Sudhaker Rao
Therapy ◽  
2021 ◽  
Vol 6_2021 ◽  
pp. 128-135
Author(s):  
Pogosyan K.A. Pogosyan ◽  
Karonova Т.L. Karonova ◽  
Yanevskaya L.G. Yanevskaya ◽  
Andreeva А.Т. Andreeva ◽  
Ryzhkova D.V. Ryzhkova ◽  
...  

2010 ◽  
Vol 7 (3) ◽  
pp. 43-48
Author(s):  
N G Mokrysheva ◽  
A Yu Tokmakova ◽  
I A Voronkova ◽  
L Ya Rozhinskaya ◽  
A I Bukhman ◽  
...  

In this article we describe a clinical case of primary hyperparathyroidism, gout tophus and diabetes mellitus type 2. The relationship between hyperuricemia and hypercalcemia linked to primary hyperparathyroidism is discussed.


2019 ◽  
Vol 22 (4) ◽  
pp. 392-398
Author(s):  
Anna M. Gorbacheva ◽  
Nataliya V. Zaytseva

Hyperparathyroidism is a relatively frequent condition characterized by hypersecretion of parathyroid hormone. There are several forms of primary hyperparathyroidism. Each form affects its target region. In the visceral form, nephrocalcinosis, nephrolithiasis and peptic and duodenal ulcers are common. The pancreas is also a target organ. This article describes a clinical case of a patient with diabetes mellitus and previously treated primary hyperparathyroidism. The patient was admitted to the hospital due to poor glycaemic control. During the hospitalization, diabetes mellitus developed as a consequence of frequent relapses of chronic pancreatitis (outcome of the visceral form of primary hyperparathyroidism and severe hypertriglyceridemia). Glycaemic control was achieved after treatment of acute pancreatitis and insulin administration. This clinical case is an example of the impact of previous primary hyperparathyroidism (even after radical treatment and remission) on the development of a multi-faceted comorbidity.


1988 ◽  
Vol 207 (4) ◽  
pp. 430-433 ◽  
Author(s):  
MICHAEL P. BANNON ◽  
JON A. VAN HEERDEN ◽  
P. J. PALUMBO ◽  
DUANE M. ILSTRUP

2008 ◽  
Vol 14 (1) ◽  
pp. 69-75 ◽  
Author(s):  
Monica Cardenas ◽  
Karen Vigil ◽  
Gary Talpos ◽  
Min Lee ◽  
Edward Peterson ◽  
...  

2021 ◽  
Vol 67 (4) ◽  
pp. 4-7
Author(s):  
N. G. Mokrysheva ◽  
E. V. Kovaleva ◽  
A. K. Eremkina

The most important and effective way to organize nationwide the healthcare, as well as monitoring and routing for patients with endocrine diseases, is the creation of an unified medical record (Endocard). The Endocard is also aimed at maximizing the opportunity for professionals and researchers on various scientific issues. Registries are the potential informational and analytical platform to achieve this goal. They include the basic information on the epidemiological and clinical features of the most severe diseases such as diabetes mellitus. Given the lack of large-scale epidemiological data on the parathyroid glands pathology — primary hyperparathyroidism and hypoparathyroidism — the registers of these diseases that collects a common dataset and clinician and patient reported outcomes are of particular interest.


Sign in / Sign up

Export Citation Format

Share Document